Daily Stock Market News

3 ASX healthcare penny stocks with over 15% returns in last one month

Penny stocks are the stocks that trade at a very low price usually below one dollar. The features of penny stocks are as follows:

  • Due to their low price, investors with a small budget can also invest in them
  • Penny stocks are generally issued by companies in their growth phase, which provides a good scope of high returns in future
  • Penny stocks are risky as well; they can be potential value trap stocks

Before investing in penny stocks, one should do good research of the company and find out why they are trading at low prices.

This article will discuss three penny stocks from the ASX healthcare sector that have provided more than 15% returns to the investors over the last month.

Data source: ASX as of 28 Feb 2022

Cronos Australia Limited (ASX: CAU)

Cronos Australia specialises in the development and sales of cannabinoid-based products. The share price of CAU has increased by nearly 27% over the last month. The stock has also performed excellently in the last 52 weeks with nearly 136% returns.

In the half-year period ended 31 December 2021, the company reported a profit after income tax of AU$3.4 million, an increase of over 1,133% as compared to the previous corresponding period (PCP). The company’s total revenues also surged by 272.6% year-on-year.

As the company and CDA Health Pty. Ltd. (CDA) merged in December last year, the results included the revenues and expenses of the CDA Health operations for the full half-year ended 31 Dec 2021 and those of the pre-merger Cronos Australia operations for the period from 16 Dec 2021 to 31 Dec 2021.

Related read: Cronos Australia (ASX: CAU) shares rise on merger news

TALi Digital Limited (ASX: TD1)

TD1 develops products to develop cognitive function

Image source: ©  Skypixel   | Megapixl.com 

TALi Digital Limited is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The company has provided a return of nearly 19% to its shareholders in the last month.

TD1 has reported a loss of approximately AU$2.6 million for the half-year ended 31 December 2021.

During the period, TALi entered a Strategic Licensing Agreement with Akili Interactive Labs, Inc., a worldwide leader in digital therapeutics. Under the Agreement, Akili will get a license to TALi’s market-leading technology to become the exclusive commercialisation partner for all paediatric cognition products in the US, as per the August 2021 update. 

The agreement recognises the value of TALi patented technology platform, as well as generates future milestone and royalty payments. Moreover, it provides validation for additional potential partner/license agreements in the sector over future periods, the company highlighted in its first-half report.

Related read: TALI (ASX:TD1) is ready for commercialisation in India and the US

Careteq Limited (ASX: CTQ)

Careteq is a health-tech company that has developed and commercialised a suite of products for the elderly, disabled and vulnerable individuals. The share price of Careteq has increased by nearly 17% in the last month.

Below are the highlights from the recently released report for the company’s performance during 1HFY22 period ended 31 December 2021:

  • Interim revenue increased by nearly six times to AU$1.9 million
  • User base surged by 579% year-on-year
  • Net loss stood at AU$3,827,624, largely in line with 1HFY21
  • SaaS solutions have been gaining market share in Australia
  • The company has a healthy balance sheet with over AU$7 million in cash

Also read: IBX & TLX: How these two ASX healthcare stocks fared in 2021

Penny stocks are relatively volatile and prone to wild swings in their performance. Therefore, one must always do thorough research and practise due diligence before investing in these stocks.

Read More: 3 ASX healthcare penny stocks with over 15% returns in last one month

You might also like